SCHEMBL12414656

SCHEMBL12414656

CC(C)c1ncc(N2CCCC2=O)cn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 6/20 0.43
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
HTR6 P50406 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LRRK2 Q5S007 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
HPGD P15428 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
CCR6 P51684 1/20 0.38
PIP4K2A P48426 1/20 0.38
NPC1 O15118 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
USP1 O94782 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14525386 0.95 AKR1C3 (0.42) AKR1C3ALDH1A1LMNAHRH3HTR6
SCHEMBL8305588 0.81 LMNA (0.47) AKR1C3ALDH1A1LMNAHTR6L3MBTL1
SCHEMBL21509722 0.80 AKR1C3 (0.49) AKR1C3ALDH1A1HRH3CYP1A2CYP2D6
SCHEMBL26953351 0.77 ALDH1A1 (0.46) AKR1C3ALDH1A1LMNAHRH3HTR6
SCHEMBL31093334 0.77 ALDH1A1 (0.46) AKR1C3ALDH1A1LMNAHRH3HTR6
SCHEMBL14525388 0.76 PTGS2 (0.41)
SCHEMBL12414652 0.76 HTR6 (0.40) AKR1C3ALDH1A1LMNAHRH3HTR6
SCHEMBL8285962 0.76 AKR1C3 (0.45) AKR1C3ALDH1A1LMNAHRH3HTR6
SCHEMBL14525387 0.75 AKR1C3 (0.48) AKR1C3ALDH1A1HRH3CYP1A2CYP2D6
SCHEMBL8358646 0.75 AKR1C3 (0.45) AKR1C3ALDH1A1LMNAHRH3HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 AKR1C3 13/4885ALDH1A1 831/4885LMNA 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.